Accomplished R&D Leader and CRISPR Tools Expert Joins VedaBio to Drive Platform Expansion and Industrialization
SAN DIEGO--(BUSINESS WIRE)--VedaBio, a biotechnology company leading a paradigm shift in molecular detection, today announced the appointment of G. Brett Robb, Ph.D., as Senior Scientific Director and Head of CRISPR Science. With over 16 years of experience in life sciences R&D, Dr. Robb brings extensive expertise in CRISPR-Cas systems, enzyme-based tools, and RNA biology. His appointment marks a significant milestone as VedaBio advances the development and commercialization of its innovative CRISPR-based molecular detection platform.
“We are fortunate to have the chance to welcome Brett to the VedaBio team as Senior Scientific Director and Head of CRISPR Science,”said Frédéric Sweeney, Ph.D., President and CEO of VedaBio. “Brett’s extraordinary leadership, deep knowledge and strategic vision in CRISPR technology will be invaluable to us. His ability to translate scientific discoveries into best-in-class products, combined with his proven track record of success, will help drive VedaBio’s platform to the next level and into the future.”
Dr. Robb has been a driving force in CRISPR research and product development. At New England Biolabs (NEB), he established and led discovery and early development efforts for CRISPR-Cas nucleases, playing pivotal strategic and technical roles in NEB's successful entry into the CRISPR-Cas reagents market. His research and collaborations contributed to significant advancements in the field, including studies reporting CRISPR-Cas9, Cas12a, Cas12l, and Cas13d enzyme discovery, characterization, and technology development. Moreover, he coordinated over 30 industry and academic members to establish standardized genome editing terminology.
Beyond his work in CRISPR, Dr. Robb has also been a key player in the development of RNA products. He played a pivotal role in setting the vision for NEB's RNA product portfolio, positioning the company to supply critical enzymes for SARS-CoV-2 mRNA vaccine manufacturing.
“Having followed the evolution of CRISPR-based molecular detection with great interest, I’m thrilled to join the world-class team at VedaBio,” said Dr. Robb. “VedaBio’s CRISPR cascade uniquely removes the need for nucleic acid pre-amplification, expanding possibilities for diagnostic testing, including extraordinarily rapid results and high multiplexing. The technology's revolutionary potential, combined with the team’s deep understanding of the industry and proven track record of bringing innovative molecular diagnostics products to market, is truly outstanding. I’m eager to contribute to the development and applications of this groundbreaking platform and its transformative impact on healthcare.”
About VedaBio
VedaBio is revolutionizing molecular biology with its breakthrough platform for rapid molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. Our CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries. Learn more at vedabio.com.
Contacts
Karen Sharma
CG Life
